Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17135525 | FILOVIRUS ANTIBODY | December 2020 | August 2023 | Abandon | 31 | 1 | 0 | No | No |
| 16973471 | IMMUNOGENIC COMPOSITION | December 2020 | April 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17114773 | Mutated Immunoglobulin-Binding Polypeptides | December 2020 | March 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17092164 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION | November 2020 | May 2021 | Allow | 7 | 2 | 0 | Yes | No |
| 17087704 | Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines | November 2020 | October 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17052470 | ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION | November 2020 | May 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17066874 | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION | October 2020 | September 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17041790 | HUMAN WEST NILE VIRUS ANTIBODIES AND METHODS OF USE THEREFOR | September 2020 | February 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 16982036 | VACCINE COMPOSITIONS | September 2020 | June 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17019825 | Stabilized Coronavirus Spike (S) Protein Immunogens and Related Vaccines | September 2020 | November 2020 | Allow | 2 | 0 | 0 | Yes | No |
| 17009448 | DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30 NUCLEOTIDE DELETION IN THE 3'-UTR OF DENGUE TYPES 1,2,3, AND 4, OR ANTIGENIC CHIMERIC DENGUE VIRUSES 1,2,3, AND 4 | September 2020 | April 2023 | Allow | 32 | 1 | 0 | No | No |
| 16971284 | Aluminum Oxide Surfaces and Interface Molecules | August 2020 | April 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 16995439 | MULTI-CBV VACCINE FOR PREVENTING OR TREATING TYPE I DIABETES | August 2020 | February 2023 | Allow | 30 | 2 | 0 | No | No |
| 16994500 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | August 2020 | July 2023 | Allow | 35 | 1 | 1 | No | No |
| 16989796 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION | August 2020 | February 2022 | Abandon | 18 | 5 | 1 | Yes | Yes |
| 16989038 | PARAINFLUENZA VIRUS 5 BASED VACCINES | August 2020 | September 2022 | Allow | 25 | 1 | 0 | Yes | No |
| 16938105 | Engineered HCV E2 Immunogens and Related Vaccine Compositions | July 2020 | March 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 16935121 | NOVEL AAV MEDIATED INFLUENZA VACCINES | July 2020 | January 2023 | Abandon | 30 | 0 | 1 | No | No |
| 16927169 | ANTI-RSV MONOCLONAL ANTIBODY FORMULATION | July 2020 | January 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 16924032 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR INFLUENZA | July 2020 | November 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16922322 | EPSTEIN-BARR VIRUS VACCINES | July 2020 | January 2024 | Allow | 43 | 2 | 1 | Yes | Yes |
| 16959828 | POLYNUCLEOTIDES ENCODING ANTI-CHIKUNGUNYA VIRUS ANTIBODIES | July 2020 | June 2023 | Allow | 35 | 1 | 0 | No | No |
| 16946708 | ANTI-VIRAL COMPOSITIONS CONTAINING PIKFYVE INHIBITORS AND USE THEREOF | July 2020 | November 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16914829 | RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM | June 2020 | August 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16911511 | Separation Method | June 2020 | December 2022 | Allow | 30 | 2 | 0 | No | No |
| 16909313 | NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONS | June 2020 | September 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16906373 | METHOD FOR THE QUANTIFICATION OF MEASLES AND RUBELLA TARGETS | June 2020 | June 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16904793 | RSV-SPECIFIC BINDING MOLECULE | June 2020 | May 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16901410 | TRUNCATED ROTAVIRUS VP4 PROTEIN AND APPLICATION THEREOF | June 2020 | March 2022 | Allow | 21 | 0 | 0 | Yes | No |
| 16772131 | FLAVIVIRUS VACCINE | June 2020 | September 2023 | Allow | 39 | 4 | 1 | Yes | No |
| 16896991 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | June 2020 | September 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16896980 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | June 2020 | September 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16897013 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | June 2020 | April 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16897001 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | June 2020 | November 2021 | Allow | 17 | 0 | 0 | Yes | No |
| 16897027 | MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS | June 2020 | April 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 16768550 | METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS | May 2020 | August 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16768499 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | May 2020 | August 2023 | Allow | 38 | 4 | 0 | Yes | No |
| 16768402 | SAPONIN PURIFICATION | May 2020 | October 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16767737 | NOVEL METHODS OF VACCINATION USING ICOSAHEDRAL PHAGE | May 2020 | October 2022 | Abandon | 29 | 1 | 1 | Yes | No |
| 16884475 | Separation Method | May 2020 | May 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 15931787 | COMBINATION IMMUNOTHERAPIES FOR TREATMENT OF CANCER | May 2020 | February 2022 | Allow | 21 | 2 | 1 | Yes | No |
| 16763013 | Compositions And Methods for Enhancing Production, Growth, Spread, or Oncolytic and Immunotherapeutic Efficacy of Interferon-Sensitive Viruses | May 2020 | November 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16762836 | RECOMBINANT VECTORS ENCODING ZIKA VIRUS PROTEIN SUBUNITS | May 2020 | April 2023 | Allow | 35 | 2 | 0 | No | No |
| 16864566 | HUMAN CYTOMEGALOVIRUS VACCINE | May 2020 | August 2021 | Allow | 15 | 0 | 0 | Yes | No |
| 16855046 | Risk Stratification for Contagious Disease | April 2020 | August 2021 | Abandon | 15 | 2 | 0 | Yes | No |
| 16753018 | GENE THERAPIES FOR LYSOSOMAL DISORDERS | April 2020 | July 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16652705 | CHIMERIC YELLOW FEVER ZIKA VIRUS STRAIN | April 2020 | February 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 16652902 | Compositions for Booster Vaccination Against Dengue | April 2020 | February 2023 | Allow | 34 | 4 | 0 | Yes | No |
| 16651061 | MUTATED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR CHEMICAL COUPLING OF LIGANDS, NANOPARTICLES OR DRUGS VIA THIOETHER BINDING AND PRODUCTION METHOD THEREOF | March 2020 | May 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16826529 | VACCINE DEVELOPMENT METHODOLOGY BASED ON AN ADHESION MOLECULE | March 2020 | October 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16649567 | TOBAMOVIRUS-BASED VIRUS-LIKE PARTICLES AND VACCINES | March 2020 | November 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16820462 | ALPHAVIRUS AND COMPOSITIONS, METHODS, AND KITS RELATED THERETO | March 2020 | April 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 16813179 | METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUS | March 2020 | July 2022 | Abandon | 29 | 1 | 0 | No | No |
| 16645788 | Mammal-specific Growth-defective Arbovirus | March 2020 | May 2024 | Allow | 50 | 3 | 1 | No | Yes |
| 16645417 | FILOVIRUS VACCINES AND METHODS OF USE | March 2020 | December 2021 | Abandon | 21 | 1 | 1 | No | No |
| 16803937 | DELIVERY OF BIOMOLECULES TO PBMCs TO MODIFY AN IMMUNE RESPONSE | February 2020 | February 2023 | Allow | 35 | 3 | 0 | No | No |
| 16794854 | LENTIVIRAL VECTOR-BASED JAPANESE ENCEPHALITIS IMMUNOGENIC COMPOSITION | February 2020 | August 2023 | Allow | 41 | 4 | 0 | Yes | No |
| 16790289 | ANTI-DENGUE VIRUS ANTIBODIES AND USES THEREOF | February 2020 | November 2022 | Abandon | 33 | 2 | 1 | No | No |
| 16788182 | HMPV/HPIV3 MRNA VACCINE COMPOSITION | February 2020 | February 2022 | Allow | 24 | 1 | 0 | No | No |
| 16781782 | LIQUID FLOURESCENT DYE CONCENTRATE FOR FLOW CYTOMETRY EVALUATION OF VIRUS-SIZE PARTICLES AND RELATED PRODUCTS AND METHODS | February 2020 | February 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16779807 | UTILITIES OF STIMULATED WHOLE BLOOD CULTURE SYSTEMS | February 2020 | November 2023 | Allow | 45 | 3 | 1 | No | No |
| 16636094 | COMPOSITIONS AND METHODS FOR DELIVERY OF AAV | February 2020 | July 2022 | Allow | 29 | 0 | 0 | Yes | No |
| 16745986 | DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES | January 2020 | June 2021 | Allow | 17 | 0 | 0 | No | No |
| 16631557 | CHIKUNGUNYA VIRUS ANTIGEN CONSTRUCTS | January 2020 | January 2023 | Allow | 36 | 1 | 1 | No | No |
| 16743415 | AAV CAPSID PRODUCTION IN INSECT CELLS | January 2020 | January 2023 | Allow | 36 | 0 | 1 | No | No |
| 16629339 | TREATMENT OF SPINAL MUSCULAR ATROPHY | January 2020 | July 2022 | Allow | 30 | 1 | 0 | No | No |
| 16628057 | A SYNTHETIC POLYPEPTIDE EPITOPE BASED VACCINE COMPOSITION | January 2020 | January 2022 | Allow | 24 | 0 | 0 | Yes | No |
| 16722393 | THERMAL INACTIVATION OF ROTAVIRUS | December 2019 | April 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16623026 | COMPOSITIONS AND ADMINISTRATION OF CHIMERIC GLYCOPROTEIN LYSSAVIRUS VACCINES FOR COVERAGE AGAINST RABIES | December 2019 | June 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16714370 | COMPOSITIONS AND METHODS FOR CANCER THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS | December 2019 | March 2022 | Abandon | 27 | 2 | 0 | No | No |
| 16708797 | Recombinant Antigen Derived From Zika Virus E Protein And Use Thereof | December 2019 | December 2021 | Allow | 24 | 1 | 1 | Yes | No |
| 16707961 | Methods for Culturing and for Detecting Stealth Adapted Viruses | December 2019 | May 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16620581 | Zika Virus Like Particle (VLP) Based Vaccine and Microneutralization Assay | December 2019 | November 2021 | Allow | 23 | 2 | 1 | Yes | No |
| 16692488 | METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES | November 2019 | August 2021 | Allow | 20 | 1 | 0 | No | No |
| 16615652 | EXPRESSION VECTORS AND RELATED METHODS OF DELIVERY OF Na/K ATPASE/Src RECEPTOR COMPLEX ANTAGONISTS | November 2019 | July 2024 | Abandon | 55 | 3 | 1 | Yes | No |
| 16612221 | TARGETED PREVENTION OF MATERNAL TO FOETAL VERTICAL TRANSMISSION OF INFECTION | November 2019 | January 2023 | Allow | 39 | 3 | 1 | Yes | No |
| 16612352 | ALPHAVIRUS NEOANTIGEN VECTORS | November 2019 | January 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16611786 | RECOMBINANT MEASLES VACCINE EXPRESSING HTERT | November 2019 | January 2022 | Allow | 27 | 1 | 0 | No | No |
| 16672168 | HUMAN ROTAVIRUS STRAINS AND VACCINES | November 2019 | March 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16669401 | COMPOSITIONS AND METHODS FOR PRODUCTION OF COLD-CHAIN VACCINES | October 2019 | January 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16665708 | T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA | October 2019 | July 2021 | Allow | 20 | 0 | 1 | Yes | No |
| 16594763 | Devices, Systems, and Methods for Aiding in the Detection of a Physiological Abnormality | October 2019 | November 2022 | Allow | 37 | 5 | 0 | Yes | No |
| 16595288 | METHODS AND COMPOSITIONS FOR ACTIVATION OF INNATE IMMUNE RESPONSES THROUGH RIG-I LIKE RECEPTOR SIGNALING | October 2019 | January 2022 | Allow | 27 | 2 | 0 | Yes | No |
| 16589751 | STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES | October 2019 | February 2021 | Allow | 16 | 0 | 0 | No | No |
| 16589601 | VACCINE AGAINST RSV | October 2019 | July 2021 | Allow | 21 | 1 | 0 | Yes | No |
| 16497574 | CHIMERIC INSECT-SPECIFIC FLAVIVIRUSES | September 2019 | August 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16578748 | RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE | September 2019 | January 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16566542 | IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN ANTIBODY AGAINST RSV PREFUSION F PROTEIN | September 2019 | September 2021 | Allow | 25 | 2 | 0 | Yes | No |
| 16561755 | Compositions and Methods for Dengue Virus Chimeric Constructs in Vaccines | September 2019 | October 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16555912 | METHODS AND COMPOSITIONS FOR RECOMBINANT DENGUE VIRUSES FOR VACCINE AND DIAGNOSTIC DEVELOPMENT | August 2019 | August 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16553213 | COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS | August 2019 | April 2022 | Abandon | 31 | 2 | 1 | Yes | No |
| 16548309 | Multi-Specific Antibodies for Cross-Neutralization of Multiple Filovirus Glycoproteins | August 2019 | June 2021 | Allow | 21 | 1 | 0 | No | No |
| 16545777 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | August 2019 | November 2019 | Allow | 2 | 0 | 0 | Yes | No |
| 16542742 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | August 2019 | October 2019 | Allow | 2 | 0 | 0 | Yes | No |
| 16602348 | Methods for assessing risk of developing a viral of disease using a genetic test | August 2019 | October 2020 | Allow | 14 | 0 | 1 | Yes | No |
| 16536531 | Anti-Zika Virus Antibodies and Methods of Use | August 2019 | May 2021 | Allow | 21 | 1 | 0 | No | No |
| 16528710 | IMMUNOASSAY USING AT LEAST TWO PEGYLATED ANALYTE-SPECIFIC BINDING AGENTS | August 2019 | April 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16523802 | MUTATED PARVOVIRUS STRUCTURAL PROTEINS AS VACCINES | July 2019 | July 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16480671 | VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF | July 2019 | April 2024 | Allow | 57 | 4 | 1 | Yes | No |
| 16513263 | MATERIALS AND METHODS FOR PRODUCING IMPROVED LENTIVIRAL VECTOR PARTICLES | July 2019 | December 2020 | Allow | 17 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEN, STACY BROWN.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHEN, STACY BROWN works in Art Unit 1648 and has examined 976 patent applications in our dataset. With an allowance rate of 51.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner CHEN, STACY BROWN's allowance rate of 51.1% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEN, STACY BROWN receive 2.08 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHEN, STACY BROWN is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +55.3% benefit to allowance rate for applications examined by CHEN, STACY BROWN. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.8% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.8% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 87.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 74.2% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 65.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 64.8% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 6.0% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.6% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.